Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

SNMMI Names Helen Nadel, MD, FRCPC, as President-Elect at 2022 Annual Meeting
News | SNMMI
SNMMI Names Helen Nadel, MD, FRCPC, as President-Elect at 2022 Annual Meeting

June 15, 2022 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at ...

Time June 15, 2022
arrow
Representative axial image from a test set imaging study. From top left to bottom right: CT (A), NAC-PET (B), original AC-PET (C), AI-generated AC-PET (D). The blue arrow indicates one lesion that was observed in both images, and the red arrow indicates a lesion that was missed (i.e., not de-tected by expert nuclear medicine physicians) in AI image. NAC = Non-Attenuation Corrected. AC = Attenuation-Corrected
News | PET-CT
Virtual CT Scans Cut Patient Radiation Exposure in Half During PET/CT Studies

June 14, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and ...

Time June 14, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.
News | SNMMI
SNMMI Launches Mars Shot Fund for Nuclear Medicine Research

June 14, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot ...

Time June 14, 2022
arrow
Offers enhanced SPECT and CT imaging functionalities, including 64-slice CT and automated SPECT motion correction, as well as automated workflow
News | SPECT-CT
Siemens Healthineers Announces FDA Clearance of Symbia Pro.specta SPECT/CT Scanner

June 13, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Symbia Pro ...

Time June 13, 2022
arrow
SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada.
News | Radiopharmaceuticals and Tracers
SpectronRx to Showcase New Facility for the Global Supply of Actinium-225 at SNMMI 2022

June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences ...

Time June 13, 2022
arrow
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

June 8, 2022 — NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and ...

Time June 08, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 08, 2022
arrow
Patented artificial intelligence technology eliminates the need for gadolinium-based contrast agents in MRI exams
News | Artificial Intelligence
Imaging Biometrics Submits FDA 510(k) Application for IB Zero G

May 31, 2022 — Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, announced it has submitted an FDA 510(k) ...

Time May 31, 2022
arrow
The global nuclear medicine market size is expected to reach $24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030.
Feature | Nuclear Imaging
Global Nuclear Medicine Market Analysis Report

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare Omnipaque iohexol iodinated contrast media (ICM) for radiologic examinations.
News | Contrast Media
New Report Provides Strategies for Managing Contrast Shortage

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
Decision tree for manual review of currently scheduled contrast-enhanced CT examinations in the event that iodinated contrast supply is critically low. CECT = contrast-enhanced CT. GBCA = gadolinium-based contrast agent. NCCT = non-contrast CT. US = ultrasound.
News | Contrast Media
AJR Publishes Best Practices for Iodinated Contrast Media Shortage

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
Dr. Clifford Cassidy, an Assistant Professor in the University of Ottawa's Faculty of Medicine’s Department of Cellular & Molecular Medicine (CMM) and a scientist at The Royal's Institute of Mental Health Research (IMHR), is the paper’s first author. Image courtesy of the Faculty of Medicine, University of Ottawa
News | Magnetic Resonance Imaging (MRI)
Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
This action has been taken out of an abundance of caution as a result of potential quality issues identified in its manufacturing processes
News | Nuclear Imaging
Novartis Announces Temporary Halt in Production of Lutathera and Pluvicto

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
A schematic of the 99Mo/99mTc production system based on an electron linear accelerator and activated carbon-based 99mTc generator
News | Radiopharmaceuticals and Tracers
New Production Method Promises to End Medical Radioisotope Shortages

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

Time April 22, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) released a new online course designed to provide cardiovascular and other nuclear medicine physicians with the knowledge needed to establish a culture of safety and quality in their nuclear imaging laboratories.
News | Nuclear Imaging
New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Time April 13, 2022
arrow
RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion China has sold together with Mevion’s HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China
News | Treatment Planning
Tongji Hospital Selects RayStation

April 7, 2022 — RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion ...

Time April 07, 2022
arrow
Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).
News | Contrast Media
Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now